Patents by Inventor Yuji Sugita

Yuji Sugita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9835544
    Abstract: According to an embodiment, a bonding strength test device measures bonding strength between a flexure of a suspension of a hard disk drive and microactuators mounted on a gimbal of the flexure. The bonding strength test device includes a clamp, dummy, and device body. The clamp fixes the flexure. The dummy is adhered to the microactuators. The probe is engaged in the dummy. The device body measures a tensile load applied to the probe while the probe is pulled toward a direction to be apart from the flexure.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 5, 2017
    Assignee: NHK SPRING CO., LTD.
    Inventors: Hideki Kashima, Yuji Sugita, Takeshi Shimoda, Tsutomu Fukuda
  • Publication number: 20160282257
    Abstract: According to an embodiment, a bonding strength test device measures bonding strength between a flexure of a suspension of a hard disk drive and microactuators mounted on a gimbal of the flexure. The bonding strength test device includes a clamp, dummy, and device body. The clamp fixes the flexure. The dummy is adhered to the microactuators. The probe is engaged in the dummy. The device body measures a tensile load applied to the probe while the probe is pulled toward a direction to be apart from the flexure.
    Type: Application
    Filed: March 3, 2016
    Publication date: September 29, 2016
    Applicant: NHK SPRING CO., LTD.
    Inventors: Hideki KASHIMA, Yuji SUGITA, Takeshi SHIMODA, Tsutomu FUKUDA
  • Patent number: 7172867
    Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: February 6, 2007
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
  • Patent number: 7160683
    Abstract: SCCA1 and SCCA2 genes, whose expression were greatly changed in a plurality of cells by stimulating respiratory tract epithelial cells with IL-4 or IL-13, were obtained as allergy related genes. Furthermore, elevation of blood level of expression products of these genes accompanying bronchial asthmatic attack was elucidated. This invention provides a method of testing for bronchial asthmatic attack that uses as indicators, expression levels of these genes in biological samples.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: January 9, 2007
    Assignee: Genox Research, Inc.
    Inventors: Noriko Ohtani, Keiko Matsui, Nei Yoshida, Yuji Sugita, Yuhei Hamasaki, Kenji Izuhara
  • Patent number: 7148011
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: December 12, 2006
    Assignees: Japan as represented by General Director of Agency of National Center for Child Health and Development, Eisai Co., Ltd., Genox Research, Inc.
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Gozoh Tsujimoto, Eiki Takahashi
  • Patent number: 7115373
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: October 3, 2006
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center For Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Patent number: 6986990
    Abstract: T cells from multiple subjects who showed different cedar pollen specific IgE titers were prepared before and after cedar pollen dispersal, and differential display analysis was performed to screen for pollen antigen responsive genes. As a result, a novel gene was successfully isolated whose expression is significantly higher in subjects with high cedar pollen specific IgE titer. The inventors have found that it is possible to use this gene to test for an allergic disease and to screen for candidate compounds for therapeutic drugs for an allergic disease.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: January 17, 2006
    Assignee: Genox Research, Inc.
    Inventors: Takeshi Nagasu, Yuji Sugita, Tomoko Fujishima, Tadahiro Oshida, Masaya Obayashi, Shigemichi Gunji, Izumi Obayashi, Yukiho Imai, Nei Yoshida, Kaoru Ogawa, Keiko Matsui
  • Publication number: 20050208496
    Abstract: An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases.
    Type: Application
    Filed: July 31, 2003
    Publication date: September 22, 2005
    Applicant: Genox Research, Inc.
    Inventors: Noriko Ohtani, Yuji Sugita, Mutsuo Yamaya, Hiroshi Kubo, Hiroichi Nagai, Kenji Izuhara
  • Publication number: 20040214231
    Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
    Type: Application
    Filed: July 1, 2003
    Publication date: October 28, 2004
    Applicants: Genox Research, Inc., Japan as Rep. by General Director of Agency of National Center for Child Health and Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040214192
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Application
    Filed: June 27, 2003
    Publication date: October 28, 2004
    Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040197786
    Abstract: RING6 and HLA-DMB are described herein as genes whose expression levels in mononuclear cells greatly differ between a steroid responder group and a poor steroid responder group in atopic dermatitis patients. Specifically, the expression levels of the RING6 and HLA-DMB genes were demonstrated to be reduced in steroid-responsive patients. Using the expression level of such genes in biological samples as markers of steroid responsiveness, the present invention provides a method of testing for steroid responsiveness and a method of screening for compounds that may be used to improve steroid responsiveness.
    Type: Application
    Filed: May 25, 2004
    Publication date: October 7, 2004
    Inventors: Yuji Sugita, Masayuki Heishi, Shinji Kagaya, Shigemichi Gunji, Gozoh Tsujimoto
  • Publication number: 20040161746
    Abstract: The present inventors collected blood samples from a plurality of normal healthy subjects and allergic disease patients, and conducted the differential display analysis to search for a gene that shows a difference in its expression among them. As a result, the inventors succeeded in isolating the B1153 gene whose expression level is significantly high in the allergic disease patient group. The inventors found it possible to utilize this gene in testing for an allergic disease, and screening for a candidate compound for a therapeutic agent for an allergic disease.
    Type: Application
    Filed: March 24, 2003
    Publication date: August 19, 2004
    Inventors: Yoshiko Matsumoto, Yukiho Imai, Tadahiro Oshida, Yuji Sugita, Takeshi Nagasu, Gozoh Tsujimoto
  • Publication number: 20040058351
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils of patients with atopic dermatitis. As a result, 17 genes showing a significant increase in expression in eosinophils of light patients were isolated. These gene are usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Application
    Filed: August 11, 2003
    Publication date: March 25, 2004
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Takeshi Nagasu, Hirohisa Saito, Masaya Obayashi
  • Publication number: 20040053282
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils of patients with atopic dermatitis. As a result, intersectin 2 was isolated as a gene showing a significant increase in expression in eosinophils of light patients. The gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Application
    Filed: August 11, 2003
    Publication date: March 18, 2004
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Takeshi Nagasu, Eiki Takahashi, Hirohisa Saito, Masaya Obayashi
  • Publication number: 20040038252
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Application
    Filed: July 31, 2003
    Publication date: February 26, 2004
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Gozoh Tsujimoto, Eiki Takahashi
  • Publication number: 20040023263
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, genes “2259-01”, “2298-09”, “2255-02”, “2292-04”, and “2182-02” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. These genes are usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Application
    Filed: August 6, 2003
    Publication date: February 5, 2004
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Hirohisa Saito
  • Publication number: 20030224423
    Abstract: B1799 gene, whose expression level increases significantly in the patient group, was successfully identified by screening for a gene which shows difference in expression in blood collected from multiple healthy subjects and patients of allergic diseases employing the differential display method. The gene expression level is specifically high in T cells and increased due to T cell activation. This gene can be used in testing for allergic diseases and also in screening for therapeutic agents for allergic diseases.
    Type: Application
    Filed: April 3, 2003
    Publication date: December 4, 2003
    Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Yoshiko Matsumoto, Yukiho Imai, Nei Yoshida, Tadahiro Oshida, Yuji Sugita, Hirohisa Saito
  • Publication number: 20030219796
    Abstract: The SOCS3 gene has been identified as a gene whose expression level in T cells of patients with an atopic disorder is significantly higher than that of the normal healthy subjects. The present inventors found that this gene can be used in testing for allergic diseases and in screening for therapeutic agents. The present invention enables screening for compounds useful in the treatment of allergic diseases.
    Type: Application
    Filed: February 27, 2003
    Publication date: November 27, 2003
    Applicants: Genox Research, Inc., Japan as represented by general director of agency of National Center for Child Health & Development
    Inventors: Naoko Nagata, Tadahiro Oshida, Yuji Sugita, Masato Kubo, Hirohisa Saito
  • Publication number: 20030152956
    Abstract: Six genes, whose expressions were greatly changed in a plurality of cells by stimulating respiratory tract epithelial cells with IL-4 or IL-13, were obtained as allergy related genes. This invention provides a method of testing for allergic diseases, and method of screening for compounds useful in treating such diseases, that use as indicators, expression levels of these genes in biological samples.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 14, 2003
    Inventors: Noriko Ohtani, Keiko Matsui, Nei Yoshida, Yuji Sugita, Kenji Izuhara
  • Publication number: 20030148312
    Abstract: An objective of the present invention is to provide a method for testing for an allergic disease and a method of screening for a therapeutic agent for allergic diseases.
    Type: Application
    Filed: July 24, 2002
    Publication date: August 7, 2003
    Applicant: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
    Inventors: Nei Yoshida, Naoko Nagata, Tadahiro Oshida, Ryoichi Hashida, Yuji Sugita, Hirohisa Saito